Eddie Hickman
Stock Analyst at Guggenheim
(3.24)
# 994
Out of 4,784 analysts
14
Total ratings
57.14%
Success rate
13.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $7.85 | +180.25% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $11.06 | +189.33% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $6.72 | +420.83% | 1 | Mar 13, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | n/a | $0.70 | - | 1 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $75 → $78 | $51.74 | +50.75% | 7 | Feb 26, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.32 | +809.09% | 3 | Jan 17, 2025 |
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $7.85
Upside: +180.25%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $11.06
Upside: +189.33%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $6.72
Upside: +420.83%
ProMIS Neurosciences
Feb 26, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.70
Upside: -
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Buy
Price Target: $75 → $78
Current: $51.74
Upside: +50.75%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.32
Upside: +809.09%